Compare Bristol-Myers Squibb Co (BMY) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Oatly Group AB - ADR — how do they compare? Bristol-Myers Squibb Co trades at $58.6 (market cap $116.30B), while Oatly Group AB - ADR trades at $9.98 (market cap $304.76M). The key difference: Bristol-Myers Squibb Co is far larger — about 381.6× Oatly Group AB - ADR's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| BMY | OTLY | |
|---|---|---|
Market Cap | $116.30B | $304.76M |
Sector | Health | Consumer Staples |
52-Week High | $62.37 | $18.54 |
52-Week Low | $42.60 | $8.03 |
Enterprise Value | $152.24B | $802.37M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Oatly (OTLY) trades at $10.00, up 1.52% today, showing modest momentum despite ongoing financial challenges. The company maintains a low P/S ratio of 0.35 but suffers from negative profitability metrics including a -17.06% net income margin and -245.57% ROE. Recent Q1 2026 earnings beat expectations with a smaller loss than projected, while technical indicators show mixed signals with an overall bullish bias. Cash flow remains negative but has improved from previous years, with operating cash burn narrowing to -$24 million in 2025.
Oatly faces significant execution risks with persistent losses and high debt levels (66.53% debt-to-asset ratio), though revenue growth continues and cash burn shows improvement. Analyst sentiment is divided with 44% buy ratings but 50% hold recommendations, reflecting cautious optimism about the company's turnaround potential amid competitive pressures in the plant-based beverage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
